LGALS1 and hepatocellular carcinoma: Additionally, targeting Gal1 has been shown to enhance the efficacy of anti‐PD1 therapy, suggesting a novel combination treatment strategy and predictive biomarker for immunotherapy in HCC (Figure 7).